pioglitazone has been researched along with Hyperemia in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Hyperemia: The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effects of pioglitazone (30 mg once daily for 16 weeks) on insulin sensitivity, insulin-mediated vasodilation, vascular inflammatory markers, fat distribution and lipids in Asian Indians and Caucasians of European ancestry." | 7.73 | Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians. ( Gerhard-Herman, MD; O'connor, ME; Raji, A; Simonson, DC; Williams, JS, 2006) |
| "To determine the effects of pioglitazone (30 mg once daily for 16 weeks) on insulin sensitivity, insulin-mediated vasodilation, vascular inflammatory markers, fat distribution and lipids in Asian Indians and Caucasians of European ancestry." | 3.73 | Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians. ( Gerhard-Herman, MD; O'connor, ME; Raji, A; Simonson, DC; Williams, JS, 2006) |
| "The study included 15 subjects with type 2 diabetes with normoalbuminuria (age, 60." | 2.73 | Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. ( Kashiwagi, A; Maeda, K; Maegawa, H; Nakao, K; Nishio, Y; Ugi, S; Uzu, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Raji, A | 1 |
| Gerhard-Herman, MD | 1 |
| Williams, JS | 1 |
| O'connor, ME | 1 |
| Simonson, DC | 1 |
| Maegawa, H | 1 |
| Nishio, Y | 1 |
| Nakao, K | 1 |
| Ugi, S | 1 |
| Maeda, K | 1 |
| Uzu, T | 1 |
| Kashiwagi, A | 1 |
1 trial available for pioglitazone and Hyperemia
| Article | Year |
|---|---|
Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes.
Topics: Adiponectin; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2007 |
1 other study available for pioglitazone and Hyperemia
| Article | Year |
|---|---|
Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians.
Topics: Adipose Tissue; Administration, Sublingual; Adult; Aged; Biomarkers; Blood Glucose; Brachial Artery; | 2006 |